MOTS - Motus GI Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.7100
-0.0100 (-0.21%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.7200
Open4.7282
Bid3.9000 x 1100
Ask7.6300 x 1000
Day's Range4.4100 - 4.7282
52 Week Range3.7500 - 7.8500
Volume39,350
Avg. Volume57,508
Market Cap73.357M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-1.2780
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Trade prices are not sourced from all markets
  • Business Wireyesterday

    Motus GI Enrolls First Patient in REDUCE Study of the Pure-Vu® System in Hospitalized Patients

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that it has enrolled the first patient in its REDUCE (Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement) study. The REDUCE study is a single-arm multi-center, prospective study that will utilize the Pure-Vu® System to facilitate bowel cleansing in approximately 100 hospitalized patients who are indicated for a diagnostic colonoscopy procedure. The Pure-Vu® System is a medical device that cleans the colon intra-procedurally to facilitate improved visualization during a colonoscopy procedure to enable a quality exam and has demonstrated effective cleaning in hundreds of procedures.

  • Business Wire3 days ago

    Motus GI Announces Issuance of Chinese Patent for the Pure-Vu® System

    Motus GI Holdings, Inc., (MOTS) (“Motus GI” or the "Company"), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that the Chinese Patent Office (SIPO) has granted a patent that covers the Company’s flagship product, the Pure-Vu® System. The Pure-Vu® System is a medical device that cleanses the colon during a colonoscopy procedure to facilitate improved visualization enabling a quality exam. “With colorectal cancer being one of the top three most commonly diagnosed cancers in the world, accounting for over 1.4 million new cases and 700,000 deaths, it is important that we bring the Pure-Vu® System to patients across the globe over the next several years,” said Mark Pomeranz, CEO of Motus GI.

  • Business Wire9 days ago

    Motus GI Reports 2018 First Quarter Financial Results and Provides Business Update

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today its financial results for the quarter ended March 31, 2018 and provided a business update.

  • Business Wire14 days ago

    Motus GI to Present Data at Digestive Disease Week® 2018 Showing Pure-Vu® System May Reduce Costs and Incidence of Colorectal Cancer

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that data related to the Company’s Pure-Vu® System will be presented at Digestive Disease Week® 2018 (“DDW”), being held June 2-5, 2018 in Washington, DC. The Pure-Vu® System is a medical device that cleans the colon intra-procedurally to facilitate improved visualization during a colonoscopy procedure to enable a quality exam and has demonstrated effective cleaning in hundreds of procedures.

  • Business Wirelast month

    Motus GI Bolsters Medical Advisory Board with Appointment of Seth A. Gross, MD, FACG, FASGE, AGAF

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that it has appointed Seth A.

  • Business Wire2 months ago

    Motus GI Announces 2017 Financial Results and Provides Business Outlook

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today its financial results for the year ended December 31, 2017 and provided its 2018 business outlook.

  • Business Wire2 months ago

    Motus GI Expands Intellectual Property Portfolio with New U.S. Patent Issuance for the Pure-Vu® System

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that the U.S.

  • Business Wire2 months ago

    Motus GI Announces Issuance of European Patent for the Pure-Vu® System

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that the European Patent Office has issued a patent No.

  • Business Wire2 months ago

    Motus GI to Present at the Oppenheimer 28th Annual Healthcare Conference

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that Mark Pomeranz, CEO, will present at the Oppenheimer 28th Annual Healthcare Conference in New York City on Tuesday, March 20, 2018 at 3:20 p.m.

  • Business Wire3 months ago

    Motus GI Receives CE Mark Approval for the Pure-Vu® System

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that it has received European CE mark approval for its flagship product, the Pure-Vu® System.

  • Marketwired3 months ago

    Motus GI Announces NASDAQ Closing Bell Ceremony

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that Mark Pomeranz, CEO of Motus, along with other members of the executive......

  • Marketwired3 months ago

    Motus GI Announces Closing of Initial Public Offering

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today the closing of its initial public offering of 3,500,000 shares of its ...